Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin

被引:117
作者
Castellani, P
Borsi, L
Carnemolla, B
Birò, A
Dorcaratto, A
Viale, GL
Neri, D
Zardi, L
机构
[1] Ist Nazl Ric Canc, Cell Biol Lab, I-16132 Genoa, Italy
[2] Univ Genoa, Div Neurosurg, Dept Surg Sci Anesthesiol & Organ Transplantat, Genoa, Italy
[3] Univ Genoa, Dept Surg, Genoa, Italy
[4] Swiss Fed Inst Technol, Dept Appl Biosci, Zurich, Switzerland
关键词
D O I
10.1016/S0002-9440(10)64446-X
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Different fibronectin (FN) isoforms; are generated by the alternative splicing of the primary FN transcript. We previously demonstrated that the isoform containing the extra domain B sequence of fibronectin (B-FN), a complete type-M-homology repeat, is a marker of angiogenesis that accumulates around neo-vasculature only during angiogenic processes. We produced a single-chain human recombinant antibody (scFv), L19, which reacts specifically with B-FN and selectively targets tumor vasculature in vivo. We used this scFv and an antibody against a pan-endothelial marker (Factor VIII) in a double-staining procedure on specimens of low- and high-grade astrocytomas to determine the percentage of B-FN-positive vessels, (denominating the resulting value angiogenic index [AI]). Compared to vascular density and proliferative activity (evaluated using antibodies to Factor VIII and Ki67, respectively), Al correlated better with tumor grade (1.6 +/- 2.6% and 92.0 +/- 8.7% of B-FN-positive vessels in low- and high-grade astrocytomas, respectively) and was a more precise diagnostic tool than either of the two conventional methods. In fact, discriminating analysis using these three parameters showed that only Al accurately classified 100% of the cases studied, compared to 64% and 89% correctly diagnosed by vascular density and of proliferating cells, respectively.
引用
收藏
页码:1695 / 1700
页数:6
相关论文
共 31 条
  • [1] [Anonymous], 2000, World Health Organisation Classification of Tumours: Pathology and genetics of tumours of the nervous system
  • [2] Lack of specificity of endoglin expression for tumor blood vessels
    Balza, E
    Castellani, P
    Zulstra, A
    Neri, D
    Zardi, L
    Siri, A
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (04) : 579 - 585
  • [3] Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment
    Birchler, M
    Viti, F
    Zardi, L
    Spiess, B
    Neri, D
    [J]. NATURE BIOTECHNOLOGY, 1999, 17 (10) : 984 - 988
  • [4] THE ALTERNATIVE SPLICING PATTERN OF THE TENASCIN-C PRE-MESSENGER-RNA IS CONTROLLED BY THE EXTRACELLULAR PH
    BORSI, L
    BALZA, E
    GAGGERO, B
    ALLEMANNI, G
    ZARDI, L
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (11) : 6243 - 6245
  • [5] TRANSFORMING GROWTH-FACTOR-BETA REGULATES THE SPLICING PATTERN OF FIBRONECTIN MESSENGER-RNA PRECURSOR
    BORSI, L
    CASTELLANI, P
    RISSO, AM
    LEPRINI, A
    ZARDI, L
    [J]. FEBS LETTERS, 1990, 261 (01) : 175 - 178
  • [6] BORSI L, IN PRESS INT J CANC
  • [7] CAMEMOLLA B, 1989, J CELL BIOL, V108, P1139
  • [8] Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
    Carnemolla, B
    Borsi, L
    Balza, E
    Castellani, P
    Meazza, R
    Berndt, A
    Ferrini, S
    Kosmehl, H
    Neri, D
    Zardi, L
    [J]. BLOOD, 2002, 99 (05) : 1659 - 1665
  • [9] Carnemolla B, 1996, INT J CANCER, V68, P397, DOI 10.1002/(SICI)1097-0215(19961104)68:3<397::AID-IJC20>3.0.CO
  • [10] 2-4